The federal government’s assertion that Eli Lilly and Co. violated a program to offer low-income Medicaid and Medicare patients discounted drugs was tossed by the U.S. District Court for the Southern District of Indiana in a 65-page opinion, which also hinted that Congress needs to address the problems with the 340B Drug Pricing Program.
Eli Lilly and Co. refuses to interview and hire older workers, systematically favoring recent college graduates and other younger applicants, a new lawsuit alleges.
Lucy Dollens, IndyBar Women and the Law Division Executive Committee member, recently sat down with Sonia Chen Arnold, Senior Director, Assistant General Counsel- Consumer/Customer Operations at Eli Lilly and Company.
A former Washington, D.C., lobbyist for Eli Lilly and Co. has dropped her complaint against the Indianapolis-based drugmaker, in which she had claimed a top executive made sexist comments about her, mocked her physical appearance and subjected her and other women to a hostile work environment.
Around central Indiana, employers are offering plenty of incentives to encourage their workers to get vaccinations as part of an effort to keep their office towers, stores, warehouses and factory floors safe for co-workers and visitors. But few, if any, are requiring workers to get vaccinated.
A legislative committee has overhauled a contentious proposal to require Indiana voters to submit identification numbers with mail-in ballot applications.
One of Indiana’s most prominent corporations is criticizing an Indiana proposal that opponents maintain will make mail-in voting more difficult by requiring voters to submit identification numbers with their ballot applications.
A former Washington, D.C., lobbyist for Eli Lilly and Co. claims a top executive at the company made sexist comments about her, mocked her physical appearance and subjected her and other women to a hostile work environment.
The Food and Drug Administration on Monday cleared emergency use of an experimental drug from Eli Lilly for people 12 and older with mild or moderate COVID-19 not requiring hospitalization.
No vaccine for COVID-19 has yet been approved by federal regulators, but Indiana health officials said Wednesday they expect to get an initial shipment of the first available vaccine by mid-November, and perhaps a second vaccine by December.
U.S. government officials are putting an early end to a study testing an Eli Lilly and Co. antibody drug for people hospitalized with COVID-19 because it doesn’t seem to be helping them. The Indianapolis-based drugmaker, however, is continuing to back the treatment.
Indianapolis-based Eli Lilly and Company says it has asked the U.S. government to allow emergency use of an experimental antibody therapy based on early results from a study that suggested the drug reduced symptoms, the amount of virus, hospitalizations and ER visits for patients with mild or moderate COVID-19.
The Indiana University Maurer School of Law, Eli Lilly & Co. and Roche are partnering for a virtual discussion today, “Pharmaceutical Innovations: Patents and the Politics of COVID-19.”
Eli Lilly and Co. and the Lilly Foundation announced a pledge of $25 million and 25,000 employee volunteer service hours over five years Saturday to ease the burden of racial injustice and its effects on local and national communities of color.
Seventeen new coronavirus cases have been confirmed around Indiana, jumping the state’s total to 56, health officials said Thursday. The statewide death toll remains at two.
Indiana’s largest organization that advocates for the interests of child victims of abuse has received the largest donation in its history — a $5 million grant from the Lilly Endowment. “They call it a transformational gift, and it certainly is for us,” Child Advocates CEO Cindy Booth said of the award.
Eli Lilly and Co. has won another patent-infringement lawsuit against a competitor who was preparing to launch an alternative form of the chemotherapy drug Alimta prior to its patent expiration in May 2022.
A federal agency has awarded Indiana $8.4 million to help fight the opioid epidemic by boosting access to substance abuse treatment and mental health services.
A federal judge Monday blocked a major White House initiative on prescription drug costs, saying the Trump administration lacked the legal authority to require drugmakers to disclose their prices in TV ads. The lawsuit was brought by three major manufacturers: Merck, Amgen and Indianapolis-based Eli Lilly.